首页 | 本学科首页   官方微博 | 高级检索  
     


Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial
Affiliation:1. Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea;2. Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea;3. Department of Medical Sciences, Chonnam National University Medical School, Jeollanam-do, Republic of Korea;4. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;5. Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea;6. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;7. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea;8. Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea;9. Department of Pathology, Seoul St. Mary''s Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea;10. Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea;11. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of Korea
Abstract:
Keywords:copanlisib  gemcitabine  peripheral T-cell lymphoma  relapsed or refractory  phase I/II trial
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号